Parkinson's Drug Meant to Work With Levodopa
The research team found that at the end of both trials, those taking the higher-dose version of opicapone achieved a “significant reduction” in the amount of time levodopa failed to work, which was characterized as “off-time.” This effect was not seen at the lower dosage.
Soares-da-Silva added that the higher-dose opicapone also triggered an increase in the amount of time levodopa performed well, meaning the amount of time the drug was “on” without signs of debilitating involuntary movement.
While the drug is already approved in Europe, the drug maker has not yet applied for approval in the United States. Link
Page | 1 2
Posted in: Pharma | November 18, 2014
Posted in: Pharma | February 1, 2016
Posted in: Pharma | August 25, 2014